Antibacterial activity of cefpodoxime against Branhamella catarrhalis.
The antibacterial activity of cefpodoxime against Branhamella catarrhalis was studied. All of the 65 clinical isolates tested were inhibited at and below 1.56 micrograms/ml, both at 10(7) and at 10(5) CFUs. The following was further studied on B. catarrhalis N-5 which showed average susceptibility to each drug examined. Bactericidal activity was observed at and above the MIC. Scanning and transmission electron microscopy revealed morphological changes, such as cellular swelling, bleb formation, inhibition of septum formation, and lysis, of the cells exposed to cefpodoxime at concentrations around the MIC. Cefpodoxime was poorly hydrolyzed by the beta-lactamase and it showed affinity for two penicillin-binding proteins that had approximate molecular weights of 83 and 74 kilodaltons, with I50 values of 3.7 and 2.1 micrograms/ml, respectively.
Takenouchi
T
T
Department of Microbiology, Kyoto Pharmaceutical University, Japan.
Nishino
T
T
D001426:Bacterial Proteins / Q000187:drug effects; D001667:Binding, Competitive; D015296:Ceftizoxime / Q000031:analogs & derivatives* / Q000494:pharmacology; D004795:Enzyme Stability / Q000187:drug effects; D006801:Humans; D006868:Hydrolysis; D008826:Microbial Sensitivity Tests; D008855:Microscopy, Electron, Scanning; D001936:Moraxella catarrhalis / Q000187:drug effects* / Q000254:growth & development / Q000648:ultrastructure; D011485:Protein Binding / Q000187:drug effects; D001618:beta-Lactamases / Q000378:metabolism; D000097627:Cefpodoxime Proxetil
D001426:Bacterial Proteins; D015296:Ceftizoxime; D001618:beta-Lactamases; D000097627:Cefpodoxime Proxetil